PROGgene: Gene expression based survival analysis web application for multiple cancers

Journal of Clinical Bioinformatics

Volumn 3, Issue 1, 2013, Pages

  Goswami, Chirayu P ^a   Nakshatri, Harikrishna ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Database; Kaplan; KM; Meier; mRNA; Multiple cancer; Pan cancer; Prognostic; Survival

Indexed keywords

EID: 84896339304     PISSN: None     EISSN: 20439113     Source Type: Journal    
DOI: 10.1186/2043-9113-3-22     Document Type: Article

References (23)

1. Buyse M, Loi S, van't Veer L, et al. TRANSBIG consortium: validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006, 98(17):1183-1192. 10.1093/jnci/djj329, 16954471.
2. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27(8):1160-1167. 10.1200/JCO.2008.18.1370, 2667820, 19204204.
3. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826. 10.1056/NEJMoa041588, 15591335.
4. Tan IB, Tan P. Genetics: an 18-gene signature (ColoPrint®) for colon cancer prognosis. Nat Rev Clin Oncol 2011, 8(3):131-133.
5. Yi JM, Dhir M, Van Neste L, et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res 2011, 17(6):1535-1545. 10.1158/1078-0432.CCR-10-2509, 3077819, 21278247.
6. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10(2):99-111. 10.1016/j.ccr.2006.06.016, 16904609.
7. Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006, 3(12):e12. 1360619, 16435888.
8. Hsu YC, Yuan S, Chen HY, et al. A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer. Clin Cancer Res 2009, 15(23):7309-7315. 10.1158/1078-0432.CCR-09-1572, 19920108.
9. Sergeant G, Van Eijsden R, Roskams T, Van Duppen V, Topal B. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery. BMC Cancer 2012, 12(1):527. 10.1186/1471-2407-12-527, 3599097, 23157946.
10. Iliopoulos D, Polytarchou C, Hatziapostolou M, et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2009, 2(92):ra62. 10.1126/scisignal.2000356, 2862216, 19825827.
11. Heron-Milhavet L, Khouya N, Fernandez A, Lamb NJ. Akt1 and Akt2: differentiating the aktion. Histol Histopathol 2011, 26(5):651-662.
12. Nakatani K, Thompson DA, Barthel A, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999, 274(31):21528-21532. 10.1074/jbc.274.31.21528, 10419456.
13. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486(7403):405-409. 10.1038/nature11154, 22722202.
14. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat 2010, 123(3):725-731. 10.1007/s10549-009-0674-9, 20020197.
15. Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data of 1287 patients. Endocr Relat Cancer 2012, 19(2):197-208. 10.1530/ERC-11-0329, 22277193.
16. Elfilali A, Lair S, Verbeke C, La Rosa P, Radvanyi F, Barillot E. ITTACA: a new database for integrated tumor transcriptome array and clinical data analysis. Nucleic Acids Res 2006, 34(Database issue):D613-D616. 1347385, 16381943.
17. Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2009, 2:18. 10.1186/1755-8794-2-18, 2689870, 19393097.
18. http://www.php.net.
19. http://www.mysql.com.
20. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009. 10.1056/NEJMoa021967, 12490681.
21. Schmidt M, Böhm D, Von Törne C, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008, 68(13):5405-5413. Doi: 10.1158/0008-5472.CAN-07-5206, 10.1158/0008-5472.CAN-07-5206, 18593943.
22. Yoshihara K, Tsunoda T, Shigemizu D, et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res 2012, 18(5):1374-1385. 10.1158/1078-0432.CCR-11-2725, 22241791.
23. Crijns AP, Fehrmann RS, De Jong S, Gerbens F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, Te Meerman GJ, De Vries EG, van der Zee AG. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 2009, 6(2):e24. 10.1371/journal.pmed.1000024, 2634794, 19192944.